Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Clinical Trial Protocol for LPS-Boost: Intensified [ 177 Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA–Expressing Disease. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0140-6736(21)00950-8
10.1016/s0140-6736(21)00950-8 · External reference
10.1056/nejmoa2107322
10.1056/nejmoa2107322 · External reference
10.1016/s0140-6736(24)01653-2
10.1016/s0140-6736(24)01653-2 · External reference
10.1016/s1470-2045(22)00605-2
10.1016/s1470-2045(22)00605-2 · External reference
10.1148/radiol.233460
10.1148/radiol.233460 · External reference
10.1016/s0140-6736(21)00237-3
10.1016/s0140-6736(21)00237-3 · External reference
10.2967/jnumed.116.178483
10.2967/jnumed.116.178483 · External reference
10.2967/jnumed.122.264953
10.2967/jnumed.122.264953 · External reference
10.1200/jco.2015.64.2702
10.1200/jco.2015.64.2702 · External reference
10.2967/jnumed.124.268167
10.2967/jnumed.124.268167 · External reference
Sample size calculation for the one-sample log-rank test
10.1002/pst.1654 · 2015 · External reference
Organ and tumour dosimetry of 177Lu-rhPSMA-10.1, a novel PSMA-targeted therapy: results from a phase I trial
10.1007/s00259-025-07313-z · 2025 · External reference
The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: a phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT) [abstract]
10.1016/j.annonc.2024.08.1739 · 2024 · External reference
10.2967/jnumed.121.261906
10.2967/jnumed.121.261906 · External reference
10.2967/jnumed.125.270916
10.2967/jnumed.125.270916 · External reference
Prostate-specific membrane antigen expression and response to DNA damaging agents in prostate cancer
10.1158/1078-0432.ccr-21-4531 · 2022 · External reference
10.1002/stem.318
10.1002/stem.318 · External reference
Cellular aging and senescence in cancer: a holistic review of cellular fate determinants
2024 · External reference
Imaging DNA damage response by gammaH2AX in vivo predicts treatment response to lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome
10.7150/thno.82101 · 2023 · External reference
Targeting senescence with radioactive 223Ra/Ba SAzymes enables senolytics-unlocked one-two punch strategy to boost anti-tumor immunotherapy
10.1016/j.biomaterials.2024.122915 · 2025 · External reference
Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC) [abstract]
10.1200/jco.2020.38.6_suppl.45 · 2020 · External reference
